Clinical Trial Update: Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a 24-valent pneumococcal polysaccharide conjugate vaccine for pneumococcal pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Pneumonia

Drugs mentioned

• 24-valent pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide conjugate vaccine (24-valent))

Snippet

Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Conditions: Streptococcus Pneumoniae Pneumonia | Phase 2 | Status: COMPLETED